spacer
home > epc > autumn 2003 > editor's letter
PUBLICATIONS
European Pharmaceutical Contractor

Editor's Letter

I am writing this Editor's Letter in the middle of a British heatwave; and this time we really can call it a heatwave, with temperatures soaring over 30oC, and railway lines buckling! Temperatures are currently similar to those in San Antonio in June, where the 39th Annual DIA meeting was held. This meeting continues to grow in size, and this year it was bigger than ever, my only complaint being that there wasn't enough time to visit all the exhibition stands and attend all but a sample of the sessions.

I did, however, attend several of the sessions relating to outsourcing, but was disappointed that there seems to be little progress in improving the relationship between CRO and sponsor. The 'Preferred Provider Tug of War' was one title, which gives an idea of how the relationship is often viewed. The presentations supporting this title addressed how to make

it less of a struggle, and in a different session, classified as R&D Strategy, we heard about a strategic partnership between Solvay and Quintiles, which highlights how the sponsor/CRO relationship can develop to the benefit of both parties.

Included in this issue we have an article by Blair McCallum of McKinsey that describes the assessments of the benefits of outsourcing. While this article focuses on manufacturing, the 10 commandments given at the end could apply to any outsourcing relationship. The keys are clear communication, understanding the value proposition and clearly stated plans.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Julia Lloyd-Parks
spacer
Julia Lloyd-Parks
spacer
spacer
spacer
John White
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement